Lai Hongjin, Lin Feng, Chen Nan, Wen Shu, Hu Xiao, Liu Lunxu
West China School Medicine, West China Hospital, Sichuan University, Chengdu 610041, China.
Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu 610041, China.
Zhongguo Fei Ai Za Zhi. 2018 Jan 20;21(1):57-62. doi: 10.3779/j.issn.1009-3419.2018.01.08.
With high morbidity and mortality, lung cancer is a major threat to human health and one of the focuses of tumor researches. Lung cancer stem cells (LCSCs) are regarded as a subpopulation of cells within lung cancer tissues with the capacity of self-renewal and differentiation, and might be related to tumorigenesis and heterogeneity of lung cancer. Tumor recurrence, metastasis and drug resistance of lung cancers could be clarified by LCSC hypothesis. Thus it's therapeutically prospective to target at these cells. This review summarizes the biomarkers of LCSCs and their aberrant signal pathways, as well as the therapeutic strategies targeting at LCSCs.
肺癌具有高发病率和高死亡率，是对人类健康的重大威胁，也是肿瘤研究的重点之一。肺癌干细胞（LCSCs）被认为是肺癌组织中具有自我更新和分化能力的细胞亚群，可能与肺癌的发生和异质性有关。肺癌干细胞假说可以解释肺癌的肿瘤复发、转移和耐药性。因此，针对这些细胞具有治疗前景。本文综述了肺癌干细胞的生物标志物及其异常信号通路，以及针对肺癌干细胞的治疗策略。
